aTyr Pharma (NASDAQ:ATYR) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of aTyr Pharma (NASDAQ:ATYR) from a sell rating to a hold rating in a report issued on Sunday.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of aTyr Pharma in a report on Monday, December 29th. Jefferies Financial Group reiterated a “buy” rating on shares of aTyr Pharma in a report on Friday, March 6th. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $25.67.

aTyr Pharma Trading Down 2.0%

Shares of aTyr Pharma stock opened at $0.85 on Friday. aTyr Pharma has a 12 month low of $0.64 and a 12 month high of $7.29. The firm has a market capitalization of $83.34 million, a P/E ratio of -1.08 and a beta of 0.55. The business has a fifty day simple moving average of $0.85 and a two-hundred day simple moving average of $1.24.

aTyr Pharma (NASDAQ:ATYR) last released its earnings results on Thursday, March 5th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. Analysts predict that aTyr Pharma will post -0.91 earnings per share for the current year.

Hedge Funds Weigh In On aTyr Pharma

Hedge funds have recently bought and sold shares of the company. Profund Advisors LLC bought a new stake in aTyr Pharma during the 3rd quarter valued at about $27,000. California State Teachers Retirement System bought a new position in shares of aTyr Pharma in the second quarter worth approximately $28,000. ADAR1 Capital Management LLC lifted its stake in shares of aTyr Pharma by 35.9% in the fourth quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock worth $40,000 after buying an additional 13,385 shares in the last quarter. Kingswood Wealth Advisors LLC purchased a new stake in shares of aTyr Pharma during the fourth quarter valued at approximately $41,000. Finally, Ameritas Investment Partners Inc. purchased a new stake in shares of aTyr Pharma during the second quarter valued at approximately $45,000. Institutional investors own 61.72% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.